ClinicalTrials.gov
public full text
Public Domain
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants#1094246
- Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants#879156
- Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting#979487
- Single-Dose Study of a New Formulation of BIIB061#806066
- A Study to Evaluate HB0034 in Healthy Chinese Adult Participants#918468
Record · ID 908189
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive